Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Comprehensive Healthcare Systems, Inc. is a vertically integrated software-as-a-service (SaaS) provider specializing in digitizing healthcare administration. Its primary function is to deliver robust, cloud-based solutions for healthcare benefits administration, medical management, and third-party administration. The company's core offering is the Novus 360 platform, which streamlines processes such as claims processing, benefits administration, price transparency, medical and pharmacy benefit management, and financial recovery, allowing clients—including unions, government entities, providers, self-insured employers, and payors—to simplify workflows and enhance operational efficiency. Comprehensive Healthcare Systems, Inc. stands out for its customizable and HIPAA-compliant technology, backed by a leadership team with decades of healthcare and benefits experience. Serving the broader healthcare industry, it addresses critical administrative challenges, supporting cost control and regulatory compliance. Its solutions are integral in helping organizations provide clear, accessible, and compliant healthcare management at scale, highlighting its role as a key enabler of digital transformation in health information services.
$0.47
+$0.02 (+5.56%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-28.88% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 9.3%, steady but not accelerating. Margins contracted 2.9pp, which offsets some of the top-line progress.
Free cash flow declined 2538% versus the prior year, cash generation momentum has weakened. ROIC dropped from -31.19% to -36.34%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4M
▲ +9.3% YoY
Net Income (TTM)
-$2M
▼ -252.9% YoY
Op. Margin
-40.69%
▼ -2.9pp YoY
ROIC
-36.34%
▼ -5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -2537.8% YoY
Op. Cash Flow (TTM)
$173K
▼ -286.3% YoY
Net Debt
$3M
Cash & Equiv.
$40K
3Y CAGR: -1.4%
Continue Research
Comprehensive Healthcare Systems (CMHSF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Comprehensive Healthcare Systems scores 25/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Comprehensive Healthcare Systems scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -40.7% operating margin and a -36.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CMHSF's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.